Knockdown of c-MET induced apoptosis in ABCB1-overexpressed multidrug-resistance cancer cell lines

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Cancer Gene Therapy

• Publication date

  2015-04-24

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/cgt.2015.15PMID 25908454
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Wnt pathway activation and ABCB1 expression account for attenuation of Proteasome inhibitor-mediated apoptosis in multidrug-resistant cancer cells

  2015cited by this paper
• Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance

  2014cited by this paper
• Wnt5A regulates ABCB1 expression in multidrug-resistant cancer cells through activation of the non-canonical PKA/β-catenin pathway

  2014cited by this paper
• FZD1 activates protein kinase C delta-mediated drug-resistance in multidrug-resistant MES-SA/Dx5 cancer cells.

  2014cited by this paper
• Mechanisms of drug resistance in cancer chemotherapy: coordinated role and regulation of efflux transporters and metabolizing enzymes.

  2013cited by this paper
• Hirsutella sinensis mycelium suppresses interleukin-1β and interleukin-18 secretion by inhibiting both canonical and non-canonical inflammasomes

  2013cited by this paper
• Gene silencing of c-Met leads to brain metastasis inhibitory effects

  2013cited by this paper
• Inducible and constitutive HSP70s confer synergistic resistance against metabolic challenges.

  2013cited by this paper
• Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met

  2012cited by this paper
• MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells

  2012cited by this paper
• Knockdown of c‐Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity

  2012cited by this paper
• Abnormal expression of E‐cadherin in tumor cells is associated with poor prognosis of gastric carcinoma

  2012cited by this paper
• Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.

  2011cited by this paper
• Adenovirus-mediated siRNA targeting c-Met inhibits proliferation and invasion of small-cell lung cancer (SCLC) cells.

  2011cited by this paper
• Knockdown of c-Met inhibits cell proliferation and invasion and increases chemosensitivity to doxorubicin in human multiple myeloma U266 cells in vitro.

  2011cited by this paper
• Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib.

  2011cited by this paper
• An overview of the c-MET signaling pathway

  2011cited by this paper
• MCF-7/ADR cells (re-designated NCI/ADR-RES) are not derived from MCF-7 breast cancer cells: a loss for breast cancer multidrug-resistant research

  2011cited by this paper
• Silencing of c-Met by RNA interference inhibits the survival, proliferation, and invasion of nasopharyngeal carcinoma cells

  2011cited by this paper
• Interactions of N-desmethyl imatinib, an active metabolite of imatinib, with P-glycoprotein in human leukemia cells

  2011cited by this paper
• Mechanisms of HGF/Met Signaling to Brk and Sam68 in Breast Cancer Progression

  2011cited by this paper
• In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs

  2011cited by this paper
• Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.

  2010cited by this paper
• Molecular mechanisms of drug resistance in single-step and multi-step drug-selected cancer cells.

  2010cited by this paper
• [RNA interference targeting c-Met inhibits proliferation of human laryngeal carcinoma Hep-2 cell line in vitro and in its xenografts in nude mice].

  2010cited by this paper
• Down-regulation of c-Met expression inhibits human HCC cells growth and invasion by RNA interference.

  2010cited by this paper
• Pharmacological interplay between breast cancer resistance protein and gefitinib in epidermal growth factor receptor signaling.

  2009cited by this paper
• PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells

  2009cited by this paper
• Down-regulation of the HGF/MET autocrine loop induced by celecoxib and mediated by P-gp in MDR-positive human hepatocellular carcinoma cell line.

  2009cited by this paper
• Differential Regulation of Drug Transporter Expression by Hepatocyte Growth Factor in Primary Human Hepatocytes

  2009cited by this paper
• Targeting MET transcription as a therapeutic strategy in multiple myeloma

  2009cited by this paper
• c-Met-targeted RNA interference inhibits growth and metastasis of glioma U251 cells in vitro

  2009cited by this paper
• Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells

  2007cited by this paper
• Genetic targeting of the kinase activity of the Met receptor in cancer cells

  2007cited by this paper
• Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines.

  2006cited by this paper
• Involvement of c-Met/hepatocyte growth factor pathway in cholangiocarcinoma cell invasion and its therapeutic inhibition with small interfering RNA specific for c-Met.

  2006cited by this paper
• Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.

  2006cited by this paper
• [Effects of c-met-siRNA on the growth and invasion of hepatocellular carcinoma MHCC97-H cells].

  2006cited by this paper
• Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

  2005cited by this paper
• Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo

  2005cited by this paper
• The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants

  2004cited by this paper
• Overcoming Multidrug Resistance in Cancer: An Update on the Clinical Strategy of Inhibiting P-Glycoprotein

  2003cited by this paper
• Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein.

  2003cited by this paper
• [The reverse effect on drug-resistance against tyrosine kinase inhibitor STI571 in mdr1 and bcr-abl positive leukemic cells].

  2003cited by this paper
• MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.

  2003cited by this paper
• K252a inhibits the oncogenic properties of Met, the HGF receptor

  2002cited by this paper
• Transgenic monkeys produced by retroviral gene transfer into mature oocytes.

  2001cited by this paper
• Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network

  1996cited by this paper
• MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors.

  1995cited by this paper
• Hepatocyte growth factor increases urokinase-type plasminogen activator (u-PA) and u-PA receptor expression in Madin-Darby canine kidney epithelial cells.

  1992cited by this paper

• HGF/c-MET axis contributes to CLL cell survival by regulating multiple mechanisms making it a potential therapeutic target for CLL treatment

  2025cites this paper
• Targeting c-Met in breast cancer: From mechanisms of chemoresistance to novel therapeutic strategies

  2024cites this paper
• In vitro models to evaluate multidrug resistance in cancer cells: Biochemical and morphological techniques and pharmacological strategies

  2024cites this paper
• A new 1,2,3-triazole-indirubin hybrid suppresses tumor growth and pulmonary metastasis by mitigating the HGF/c-MET axis in hepatocellular carcinoma

  2024cites this paper
• MET-Targeting Anticancer Drugs—De Novo Design and Identification by Drug Repurposing

  2023cites this paper
• Mesenchymal Epithelial Transition Factor (MET): A Key Player in Chemotherapy Resistance and an Emerging Target for Potentiating Cancer Immunotherapy.

  2022cites this paper
• Trends and hotspots for European Journal of Medicinal Chemistry: A bibliometric study.

  2022cites this paper
• Blockade of c-Met-Mediated Signaling Pathways by E7050 Suppresses Growth and Promotes Apoptosis in Multidrug-Resistant Human Uterine Sarcoma Cells

  2022cites this paper
• Fangchinoline abrogates growth and survival of hepatocellular carcinoma by negative regulation of c‐met/HGF and its associated downstream signaling pathways

  2022cites this paper
• STAT3 mediated upregulation of C-MET signaling acts as a compensatory survival mechanism upon EGFR family inhibition in chemoresistant breast cancer cells.

  2021cites this paper
• The role of MET in chemotherapy resistance

  2021cites this paper
• Analysis of the Internal Hypoxic Environment in Solid Tumor Tissue Using a Folding Paper System.

  2021cites this paper
• OTT_A_265592 9481..9495

  2020cites this paper
• NRF2/ABCB1‐mediated efflux and PARP1‐mediated dampening of DNA damage contribute to doxorubicin resistance in chronic hypoxic HepG2 cells

  2020cites this paper
• Anti-neoplastic Effect of Ginkgolide C through Modulating c-Met Phosphorylation in Hepatocellular Carcinoma Cells

  2020cites this paper
• Identification of P-Rex1 in the Regulation of Liver Cancer Cell Proliferation and Migration via HGF/c-Met/Akt Pathway

  2020cites this paper
• A cell-based high-throughput screen identifies inhibitors that overcome P-glycoprotein (Pgp)-mediated multidrug resistance

  2020cites this paper
• PF-2341066 combined with celecoxib promotes apoptosis and inhibits proliferation in human cholangiocarcinoma QBC939 cells.

  2018cites this paper
• Quercetin reverses the doxorubicin resistance of prostate cancer cells by downregulating the expression of c-met

  2017cites this paper
• Loss of constitutive ABCB1 expression in breast cancer associated with worse prognosis

  2017cites this paper
• Spontaneous metastases in immunocompetent mice harboring a primary tumor driven by oncogene latent membrane protein 1 from Epstein–Barr virus

  2016cites this paper
• Imatinib mesylate induces apoptosis of K 562 cell by down-regulating miR-139

  2016cites this paper